Clinical trial
Rituximab in Treating Patients With Multiple Myeloma
NCT00003554 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00003554 |
|---|---|
| Title | Rituximab in Treating Patients With Multiple Myeloma |
| Official title | Rituxan in the Management of Multiple Myeloma |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | rituximab, melphalan, prednisone |
| Start date | Nov 1, 1998 |
| Completion | Apr 1, 2004 |
| First posted | Apr 30, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: